Neeta Tandon, MA

Real-World Outcomes Post-Transition to Once-Every-Three-Month Paliperidone Palmitate in Patients With Schizophrenia Within US Commercial and Managed Care Plans

Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...

Antoine C. El Khoury , PhD;

Bruno Emond , MA;

Maryia Zhdanava , MA;

Kruti Joshi , MPH, MD;

Charmi Patel , BS , RN, BSN, MPH;

Patrick Lefebvre , MA;

Laura Morrison , MPH;

Dominic Pilon , MA;

Neeta Tandon , MA;

03/01/2019

Encounters With the Criminal Justice System in Patients With Schizophrenia or Schizoaffective Disorders Treated With Long Acting Therapy at a Community Mental Health Service Facility

Purpose: This study assessed the association between the use of Long-acting injectable (LAI) anti-psychotic drugs and encounters with the criminal justice system (CJS) among patients rece...

Madhav Bhatta , PhD;

Saroj Bista , BPharm;

Antoine C. El Khoury , PhD;

Eric Hutzell , MPH;

Douglas Smith , MD;

Neeta Tandon , MA;

03/01/2019